Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

INTRODUCTION: Prostate cancer is the second most common cancer in men worldwide. When the disease becomes resistant to androgen-deprivation therapy, treatment options are sparse. To address the high medical need in castration-resistant prostate cancer (CRPC), we generated a novel PSMAxCD3 bispecific...

Descripción completa

Detalles Bibliográficos
Autores principales: Heitmann, Jonas S, Walz, Juliane S, Pflügler, Martin, Kauer, Joseph, Schlenk, Richard F, Jung, Gundram, Salih, Helmut R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569941/
https://www.ncbi.nlm.nih.gov/pubmed/33067297
http://dx.doi.org/10.1136/bmjopen-2020-039639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569941/
https://www.ncbi.nlm.nih.gov/pubmed/33067297
http://dx.doi.org/10.1136/bmjopen-2020-039639

Ejemplares similares